Found 67 results
Filters: Author is Nussenzweig, Michel C  [Clear All Filters]
Dosenovic P, Kara EE, Pettersson A-K, McGuire AT, Gray M, Hartweger H, Thientosapol ES, Stamatatos L, Nussenzweig MC.  2018.  Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity.. Proc Natl Acad Sci U S A. 115(18):4743-4748.
Cohn LB, da Silva IT, Valieris R, Huang AS, Lorenzi JCC, Cohen YZ, Pai JA, Butler AL, Caskey M, Jankovic M et al..  2018.  Clonal CD4 T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation.. Nat Med. 24(5):604-609.
Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Lorenzi JCC et al..  2018.  Combination therapy with anti-HIV-1 antibodies maintains viral suppression.. Nature. 561(7724):479-484.
Cohen YZ, Lorenzi JCC, Seaman MS, Nogueira L, Schoofs T, Krassnig L, Butler A, Millard K, Fitzsimons T, Daniell X et al..  2018.  Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.. J Virol. 92(5)
Cohen YZ, Lorenzi JCC, Krassnig L, Barton JP, Burke L, Pai J, Lu C-L, Mendoza P, Oliveira TY, Sleckman C et al..  2018.  Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117.. J Exp Med. 215(9):2311-2324.
Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A, Seaman MS, Swihart BJ, Follmann DA, Nussenzweig MC et al..  2018.  A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.. Nat Med. 24(5):610-616.
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al..  2017.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.. Nat Med. 23(2):185-191.
Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373):pii:eaa12144.
Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens A-J, Ozorowski G et al..  2017.  Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.. J Exp Med. 214(9):2573-2590.
Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M et al..  2017.  Early antibody therapy can induce long-lasting immunity to SHIV.. Nature. 543(7646):559-563.
Mayer CT, Gazumyan A, Kara EE, Gitlin AD, Golijanin J, Viant C, Pai J, Oliveira TY, Wang Q, Escolano A et al..  2017.  The microanatomic segregation of selection by apoptosis in the germinal center.. Science. 358(6360)
Horwitz JA, Bar-On Y, Lu C-L, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS et al..  2017.  Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.. Cell. 170(4):637-648.
Escolano A, Dosenovic P, Nussenzweig MC.  2017.  Progress toward active or passive HIV-1 vaccination.. J Exp Med. 214(1):3-16.
Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R et al..  2017.  Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.. Cell. 169(4):597-609.e11.
Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV.  2016.  Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.. Cell. 165(7):1609-20.
Caskey M, Klein F, Nussenzweig MC.  2016.  Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.. N Engl J Med. 375(21):2019-2021.
Lu C-L, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A et al..  2016.  Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.. Science. 352(6288):1001-4.
Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O et al..  2016.  HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.. Immunity.
Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu C-L, Lorenzi JCC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T et al..  2016.  HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.. Nature.
Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JCC, Parrish EH, Learn GH et al..  2016.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.. Science. 352(6288):997-1001.
Gitlin AD, von Boehmer L, Gazumyan A, Shulman, iv Z, Oliveira TY, Nussenzweig MC.  2016.  Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory.. Immunity.
Escolano A, Steichen JM, Dosenovic P, Kulp DW, Golijanin J, Sok D, Freund NT, Gitlin AD, Oliveira T, Araki T et al..  2016.  Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.. Cell. 166(6):1445-1458.e12.
Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K et al..  2016.  A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.. Nature. 533(7601):105-9.
McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB et al..  2016.  Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.. Nat Commun. 7:10618.
Halper-Stromberg A, Nussenzweig MC.  2016.  Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.. J Clin Invest. 126(2):415-23.